For the last several quarters, Gilead Sciences’ earnings calls have been colored by anticipation for the launch of the California drugmaker's long-acting HIV pre-exposure prophylaxis (PrEP) option. | ...

Explore Gilead Sciences' Q3 2025 earnings: strong HIV portfolio growth, Yeztugo's rapid launch, and raised guidance.

Shiv Sena (UBT) leader and Worli legislator Aaditya Thackeray has written to Chief Minister (CM) Devendra Fadnavis, urging ...

OHE’s educational mission is to support, sustain, and enhance the discipline of health economics through increasing its accessibility, awareness, impact, reach, and relevance. As a pioneering ...

Renata Brito, Bram Janssen, Nqobile Ntshangase and Panagiotis Mouzakis delivered an innovative presentation of powerful ...

The drug can be produced for as little as $25 per person annually, but even at $2000 per person, it can reduce new US infections almost entirely, a researcher says.

We present PPTAgent, an innovative system that automatically generates presentations from documents. Drawing inspiration from human presentation creation methods, our system employs a two-step process ...

A 'game-changing' injection to prevent HIV is set to be approved for use in England and Wales. The long-acting jab will be offered on the NHS to patients who cannot have pills to protect them from the ...

In the wake of massive U.S. cuts to foreign aid, the tiny country of Lesotho in southern Africa faces deep uncertainty and worry over its HIV-positive residents.

In the wake of massive U.S. cuts to foreign aid, the tiny country of Lesotho in southern Africa faces deep uncertainty and worry over its HIV-positive residents.